Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass

Paediatric Anaesthesia

Volumn 23, Issue 3, 2013, Pages 233-241

  Gautam, Nischal K ^a   Schmitz, Michael L ^a   Harrison, Dale ^a   Zabala, Luis M ^a   Killebrew, Pamela ^a   Belcher, Ryan H ^a   Prodhan, Parthak ^a   McKamie, Wesley ^a   Norvell, Daniel C ^b  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b Spectrum Research   (United States)

Author keywords

cardiac surgery; cardiopulmonary bypass; congenital heart disease; heparin; pediatrics; protamine

Indexed keywords

HEPARIN; PROTAMINE SULFATE;

ACTIVATED CLOTTING TIME; ARTICLE; ASSAY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; BLOOD VOLUME; CARDIOPULMONARY BYPASS; CHILD; CONTROLLED STUDY; CORE TEMPERATURE; DRUG EFFICACY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PEDIATRIC SURGERY; POSTPROTAMINE HEPARIN ASSAY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOELASTOGRAPHY; WARMING;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CASE MANAGEMENT; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROTAMINES; REGRESSION ANALYSIS; THROMBELASTOGRAPHY; WHOLE BLOOD COAGULATION TIME;

EID: 84873477675     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12109     Document Type: Article

References (32)

1. DeLaria GA, Tyner J, Hayes C, et al,. Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994; 129: 944-950; discussion 950-1.
2. Griffin MJ, Rinder HM, Smith BR, et al,. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001; 93: 20-27.
3. Ellison N, Edmunds LH, Colman RW,. Platelet aggregation following heparin and protamine administration. Anesthesiology 1978; 48: 65-68.
4. Barstad RM, Stephens RW, Hamers MJ, et al,. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000; 83: 334-337.
5. Kozek-Langenecker SA, Mohammad SF, Masaki T, et al,. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 2000; 90: 808-812.
6. Ammar T, Fisher CF,. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 1997; 86: 1382-1386.
7. Chandok D, Comunale ME,. Heparin neutralization. In:, Gravlee GP, Davis RF, Stammers AH, Ungerlieder RM, eds. Cardiopulmonary Bypass Principles and Practice, 3rd edn. Philadelphia: Wolters Kluwer/Lippincott WIlliams & Williams 2008; 502-521.
8. Andrew M, Paes B, Milner R, et al,. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
9. D'Errico C, Shayevitz JR, Martindale SJ,. Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996; 10: 451-457.
10. Jaberi M, Bell WR, Benson DW,. Control of heparin therapy in open-heart surgery. J Thorac Cardiovasc Surg 1974; 67: 133-141.
11. Monagle P, Barnes C, Ignjatovic V, et al,. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95: 362-372.
12. Gruenwald CE, Manlhiot C, Crawford-Lean L, et al,. Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery. J Extra Corpor Technol 2010; 42: 9-19.
13. Codispoti M, Ludlam CA, Simpson D, et al,. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 2001; 71: 922-927; discussion 927-928.
14. Koster A, Fischer T, Praus M, et al,. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837-841.
15. Guzzetta NA, Bajaj T, Fazlollah T, et al,. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008; 106: 419-425.
16. Gruenwald CE, Manlhiot C, Chan AK, et al,. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol 2010; 56: 1794-1802.
17. Williams GD, Ramamoorthy C, Totzek FR, et al,. Comparison of the effects of red cell separation and ultrafiltration on heparin concentration during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1997; 11: 840-844.
18. Mochizuki T, Olson PJ, Szlam F, et al,. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-785.
19. Gibbs NM, Yim D, Weightman W, et al,. The effect of excess protamine on thrombelastography in vitro. Anaesth Intensive Care 2006; 34: 579-585.
20. Khan NU, Wayne CK, Barker J, et al,. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624-627.
21. Despotis GJ, Joist JH,. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999; 13 (4 Suppl 1): 18-29; discussion 36-37.
22. McCall MM, Blackwell MM, Smyre JT, et al,. Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. Ann Thorac Surg 2004; 77: 983-987; discussion 987.
23. Oliver WC, Beynen FM, Nuttall GA, et al,. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg 2003; 75: 1506-1512.
24. Elliott M,. Modified ultrafiltration and open heart surgery in children. Paediatr Anaesth 1999; 9: 1-5.
25. Cohen J, The effect size index: d. In: Cohen J, ed. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. New Jersey: Lawrence Earlbaum Associates, 1998; 2.2: 20-27.
26. Naik SK, Knight A, Elliott M,. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 1991; 84 (5 Suppl): III422-431.
27. Raymond PD, Ray MJ, Callen SN, et al,. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18: 269-276.
28. Guzzetta NA, Monitz HG, Fernandez JD, et al,. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg 2010; 111: 173-179.
29. Despotis GJ, Summerfield Al, Joist JH,. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti Xa heparin concentrations in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-1082.
30. Ni Ainle F, Preston RJS, Jenkins PV, et al,. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658-1665.
31. Mittermayr M, Margreiter J, Velik-Salchner C, et al,. Effects of protamine and heparin can be detected and easily differentiated by modified thromboelastography (Rotem®): an in vitro study. Br J Anaesth 2005; 95: 310-316.
32. Bolliger D, Szlam F, Azran M, et al,. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg 2010; 111: 601-608.